Alnylam Pharmaceuticals (ALNY) Enterprise Value (QoQ) (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) Enterprise Value (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.46% |
| Dec 31, 2025 | -95.17% |
| Sep 30, 2025 | -33.81% |
| Jun 30, 2025 | 57.57% |
| Mar 31, 2025 | -168.73% |
| Dec 31, 2024 | 11.86% |
| Sep 30, 2024 | 57.62% |
| Jun 30, 2024 | -277.24% |
| Mar 31, 2024 | 71.45% |
| Dec 31, 2023 | -132.71% |
| Sep 30, 2023 | -52.31% |
| Jun 30, 2023 | 1.87% |
| Mar 31, 2023 | 67.78% |
| Dec 31, 2022 | -97.62% |
| Sep 30, 2022 | -80.77% |
| Jun 30, 2022 | 72.53% |
| Mar 31, 2022 | -148.29% |
| Dec 31, 2021 | 23.78% |
| Sep 30, 2021 | -46.13% |
| Jun 30, 2021 | -82.88% |